We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HALO Inks Deal With INCY to Support Cancer Therapy Development
Read MoreHide Full Article
Key Takeaways
HALO grants INCY the right to ENHANZE to support subcutaneous formulations of INCA033989.
HALO will receive upfront, milestone and potential royalty payments if products are commercialized.
HALO's ENHANZE aims to enable more convenient subcutaneous dosing regimens for patients.
Halozyme Therapeutics (HALO - Free Report) announced that it has entered into a global collaboration and license agreement with Incyte (INCY - Free Report) to evaluate additional subcutaneous formulations of the latter’s INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody for a cancer indication.
With the partnership, the companies are looking to investigate additional subcutaneous formulations of Incyte’s INCA033989, utilizing Halozyme's proprietary ENHANZE drug delivery technology in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs).
The companies aim to develop more convenient subcutaneous dosing regimens that could improve the treatment experience for patients with mutCALR-expressing MPNs.
The deal gives Incyte the rights to develop and commercialize Halozyme’s ENHANZE drug delivery technology with its mutCALR development program and an option to nominate up to two additional targets for use with ENHANZE.
Per the agreement, Halozyme will receive an undisclosed amount of upfront payment from Incyte as well as additional milestone payments upon the achievement of specified development, regulatory and commercial milestones. Halozyme is also eligible to receive royalties on future net sales if a product is commercialized from this partnership using ENHANZE.
HALO’s Price Performance
Year to date, shares of Halozyme have increased 14.6% compared with the industry’s rise of 3.2%.
Image Source: Zacks Investment Research
HALO’s ENHANZE Technology Aid Revenues
Halozyme’s ENHANZE drug delivery technology has been used in the development of subcutaneous formulations of various approved drugs through partnerships with large drugmakers. The company has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s (JNJ - Free Report) Darzalex and Roche’s (RHHBY - Free Report) Phesgo.
Per the agreements, these companies have been granted worldwide license rights to develop and commercialize their products using ENHANZE technology. These deals generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Halozyme’s top line also comprises product sales, royalty payments from Roche for Phesgo and J&J for subcutaneous Darzalex as well as revenues under collaboration agreements related to its ENHANZE technology.
Halozyme’s royalty revenues totaled $240.7 million in the first quarter of 2026, up 43% from the year-ago quarter’s level. This was mainly due to the robust demand for Phesgo, subcutaneous Darzalex and Vyvgart Hytrulo, on which it earns royalties.
Management expects royalty revenues to be in the range of $1.13-$1.17 billion in 2026, implying year-over-year growth of 30% to 35%.
View the Zacks #1 Rank List
Image: Bigstock
HALO Inks Deal With INCY to Support Cancer Therapy Development
Key Takeaways
Halozyme Therapeutics (HALO - Free Report) announced that it has entered into a global collaboration and license agreement with Incyte (INCY - Free Report) to evaluate additional subcutaneous formulations of the latter’s INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody for a cancer indication.
With the partnership, the companies are looking to investigate additional subcutaneous formulations of Incyte’s INCA033989, utilizing Halozyme's proprietary ENHANZE drug delivery technology in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs).
The companies aim to develop more convenient subcutaneous dosing regimens that could improve the treatment experience for patients with mutCALR-expressing MPNs.
The deal gives Incyte the rights to develop and commercialize Halozyme’s ENHANZE drug delivery technology with its mutCALR development program and an option to nominate up to two additional targets for use with ENHANZE.
Per the agreement, Halozyme will receive an undisclosed amount of upfront payment from Incyte as well as additional milestone payments upon the achievement of specified development, regulatory and commercial milestones. Halozyme is also eligible to receive royalties on future net sales if a product is commercialized from this partnership using ENHANZE.
HALO’s Price Performance
Year to date, shares of Halozyme have increased 14.6% compared with the industry’s rise of 3.2%.
Image Source: Zacks Investment Research
HALO’s ENHANZE Technology Aid Revenues
Halozyme’s ENHANZE drug delivery technology has been used in the development of subcutaneous formulations of various approved drugs through partnerships with large drugmakers. The company has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s (JNJ - Free Report) Darzalex and Roche’s (RHHBY - Free Report) Phesgo.
Per the agreements, these companies have been granted worldwide license rights to develop and commercialize their products using ENHANZE technology. These deals generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Halozyme’s top line also comprises product sales, royalty payments from Roche for Phesgo and J&J for subcutaneous Darzalex as well as revenues under collaboration agreements related to its ENHANZE technology.
Halozyme’s royalty revenues totaled $240.7 million in the first quarter of 2026, up 43% from the year-ago quarter’s level. This was mainly due to the robust demand for Phesgo, subcutaneous Darzalex and Vyvgart Hytrulo, on which it earns royalties.
Management expects royalty revenues to be in the range of $1.13-$1.17 billion in 2026, implying year-over-year growth of 30% to 35%.
HALO’s Zacks Rank
Halozyme currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.